share_log

Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase

Benzinga Real-time News ·  Apr 1, 2021 06:03

Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase ("IAP").

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment